EGFR and breast carcinoma: Although a study reported that 11% of TNBC patients harbor EGFR gene mutations 33, other studies indicated that activating mutations in EGFR gene are rare in TNBC 34-36, which may explain the low afficacy of EGFR TKI in unselected breast cancer patients.